This is an old revision of the document!
Gastrointestinal Biomarkers
| Biomarker | Assay Purpose | Drug(s) | Diagnostic Test | Test ID |
| PD-L1 | Gastric, GEJ, esophageal adenocarcinoma; ESCC | Pembrolizumab, Nivolumab | PDL1 Dako 22C3 PharmDX | PDL1UPPERGIMARCH2026 |
| Claudin 18.2 | Gastric or GEJ adenocarcinoma | Zolbetuximab | VENTANA CLDN18 (43-14A) RxDx | BMCLAUDIN18 |
Head & Neck Biomarkers
| Biomarker | Assay Purpose | Drug(s) | Diagnostic Test | Test ID |
| PD-L1 | Advanced Head and neck squamous cell carcinoma (HNSCC) | Pembrolizumab | PDL1 Dako 22C3 PharmDX | PDL1HNSCC22C3PEMBRO |
| PD-L1 | Resectable Head and neck squamous cell carcinoma (HNSCC) | Pembrolizumab as Neoadjuvant | PDL1 Dako 22C3 PharmDX | PDL1HNSCCNEOADPEMBRO |
Gyne Biomarkers
| Biomarker | Assay Purpose | Drug(s) | Diagnostic Test | Test ID |
| PD-L1 | Cervical cancer (SCC and Adenocarcinoma) | Pembrolizumab | PDL1 Dako 22C3 PharmDX | PDL1CERVIX |
| CEP17 SISH | Ploidy Analysis | N/A | VENTANA Inform Chromosome 17 probe | MOLARCEP17 |
Lung Biomarkers
| Biomarker | Assay Purpose | Drug(s) | Diagnostic Test | Test ID |
| PD-L1 | NSCLC stage II to IIIA | Atezolizumab | PDL1 SP263 | PDL1NSCLCATEZOSP263 |
Breast Biomarkers
| Biomarker | Assay Purpose | Drug(s) | Diagnostic Test | Test ID |
| PD-L1 | Triple Negative Breast Cancer (TNBC) | Pembrolizumab | PDL1 Dako 22C3 PharmDX | PDL1TNBC22C3PEMBRO |
